Adult attention deficit hyperactivity disorder

Drug Relieves Persistent Daydreaming, Fatigue, and Brain Sluggishness in Adults with ADHD

Retrieved on: 
Tuesday, June 29, 2021
Attention deficit hyperactivity disorder, Psychiatry, Childhood psychiatric disorders, Branches of biology, Abnormal psychology, Educational psychology, Amphetamine, Methylphenidate, Sluggish cognitive tempo, Adult attention deficit hyperactivity disorder, Stimulant, Attention deficit hyperactivity disorder controversies

Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.

Key Points: 
  • Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.
  • The NYU Langone-Mount Sinai team's findings, he adds, are the first to show that such treatments also work in adults.
  • "These findings highlight the importance of assessing symptoms of sluggish cognitive tempo and executive brain function in patients when they are initially diagnosed with ADHD," says Adler.
  • Researchers then carefully tracked their psychiatric health on a weekly basis through standardized tests for signs and symptoms of sluggish cognitive tempo, ADHD, as well as other measures of brain function.

American BriVision Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD

Retrieved on: 
Tuesday, July 28, 2020
Health, Psychiatry, Articles, Childhood psychiatric disorders, Amphetamine, Methylphenidate, Educational psychology, Attention deficit hyperactivity disorder, Clinical trial, Adult attention deficit hyperactivity disorder, Attention deficit hyperactivity disorder controversies

Phase II Part II study is expected to follow after the completion of the clinical study report (CSR) of the Phase II Part I study.

Key Points: 
  • Phase II Part II study is expected to follow after the completion of the clinical study report (CSR) of the Phase II Part I study.
  • The primary objective of this study is to determine the effective doses and treatment period of ABV-1505 in adult patients with ADHD.
  • We are pleased to report the LPLV of our ABV-1505 Phase II Part I clinical trial for the treatment of adult ADHD, said Dr. Howard Doong, Chief Executive Officer of American BriVision.
  • We look forward to initiating the Phase II Part II study for adult ADHD later this year or in early 2021.

Worldwide Attention Deficit Hyperactivity Disorder Industry (2020 to 2024) - Identify Key Drugs Marketed and Prescribed

Retrieved on: 
Thursday, June 18, 2020
Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Abnormal psychology, Educational psychology, Psychiatric diagnosis, Methylphenidate, Attention deficit, Déficit, Hyperkinetic disorder, Adult attention deficit hyperactivity disorder

This report provides comprehensive insights into the Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Attention Deficit Hyperactivity Disorder pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Attention Deficit Hyperactivity Disorder market size and drug sales.
  • This research covers the following:
    Attention Deficit Hyperactivity Disorder treatment options, Attention Deficit Hyperactivity Disorder late stage clinical trials pipeline, Attention Deficit Hyperactivity Disorder prevalence by countries, Attention Deficit Hyperactivity Disorder market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Attention Deficit Hyperactivity Disorder pipeline: Find out drugs in clinical trials for the treatment of Attention Deficit Hyperactivity Disorder by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Attention Deficit Hyperactivity Disorder epidemiology: Find out the number of patients diagnosed (prevalence) with Attention Deficit Hyperactivity Disorder by countries
    Attention Deficit Hyperactivity Disorder drugs: Identify key drugs marketed and prescribed for Attention Deficit Hyperactivity Disorder in the US, including trade name, molecule name, and company
    Attention Deficit Hyperactivity Disorder drugs sales: Find out the sales value for Attention Deficit Hyperactivity Disorder drugs by countries
    Attention Deficit Hyperactivity Disorder market valuations: Find out the market size for Attention Deficit Hyperactivity Disorder drugs in 2019 by countries.

MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

Retrieved on: 
Tuesday, June 2, 2020
Health, Articles, Clinical research, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Amphetamine, Methylphenidate, Microdosing, Lysergic acid diethylamide, Master of Medicine, Adult attention deficit hyperactivity disorder, Clinical trial

BASEL, Switzerland, June 2, 2020 /PRNewswire/ --Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD.

Key Points: 
  • BASEL, Switzerland, June 2, 2020 /PRNewswire/ --Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD.
  • MindMed is specifically interested in the adult segment for ADHD as it comprises over 46.5% of the total ADHD medication market in the United States.
  • MindMed previously signed a clinical trial agreement with Maastricht University, a leader in microdosing research based in the Netherlands, as part of the same Phase 2a clinical trial.
  • In addition, the company has established a microdosing division to conduct clinical trials of LSD microdosing for adult ADHD.

American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)

Retrieved on: 
Monday, April 6, 2020
Psychiatry, Methylphenidate, Childhood psychiatric disorders, Abnormal psychology, Amphetamine, Educational psychology, Attention deficit hyperactivity disorder, Adult attention deficit hyperactivity disorder, Attention deficit hyperactivity disorder controversies

This trial is an open label, single-center and dose escalation study designed for the enrollment of six adult ADHD patients.

Key Points: 
  • This trial is an open label, single-center and dose escalation study designed for the enrollment of six adult ADHD patients.
  • As of the site monitoring visit, four qualified adult ADHD patients had been enrolled and treated with PDC-1421 Capsules.
  • Among them, two will complete their treatment of PDC-1421 according to the study protocol on April 8 and April 11, 2020 respectively.
  • The overall site monitoring visit went well with several minor errors cited and corrected subsequently.

Ironshore to Present Four Posters at the 2020 Annual American Professional Society of ADHD and Related Disorders (APSARD) Meeting

Retrieved on: 
Thursday, January 16, 2020
Biotechnology, Pharmaceutical, Health, Attention deficit hyperactivity disorder, Psychiatry, Psychology, Abnormal psychology, Psychiatric diagnosis, Childhood psychiatric disorders, Amphetamine, Educational psychology, Impulsivity, Adult attention deficit hyperactivity disorder, Hyperkinetic disorder

Ironshore Pharmaceuticals Inc. (Ironshore), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD), today announced it will present four posters at the 2020 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD) in Washington, D.C., January 17-19, 2020.

Key Points: 
  • Ironshore Pharmaceuticals Inc. (Ironshore), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD), today announced it will present four posters at the 2020 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD) in Washington, D.C., January 17-19, 2020.
  • To schedule an interview with an investigator or Ironshore executive, please contact Mrs. Sarah Pierson at [email protected] .
  • ADHD is among the most common childhood psychiatric conditions with behavioral symptoms fluctuating throughout the day.
  • JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity in people six years of age and older with ADHD.

American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)

Retrieved on: 
Thursday, December 5, 2019
Psychiatry, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Amphetamine, Methylphenidate, Abnormal psychology, Psychiatric diagnosis, Adult attention deficit hyperactivity disorder

This trial is an open label, single-center, dose escalation study to be conducted in six adult ADHD patients.

Key Points: 
  • This trial is an open label, single-center, dose escalation study to be conducted in six adult ADHD patients.
  • The primary objective of this study is to determine the effective doses and treatment period of PDC-1421 in adult patients with ADHD.
  • The secondary objective is to evaluate the safety of PDC-1421 in patents receiving the drug at various dose levels.
  • A Phase II Part II study is expected to follow at the UCSF Medical Center, along with major medical centers in Taiwan, after and assuming successful completion of this Phase II Part I study.

Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Study 2019: Includes Historic Industry Data from 2016 and Forecasts to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 20, 2019
Health, Pharmaceutical, Attention deficit hyperactivity disorder, Psychiatry, Neuroscience, Psychiatric diagnosis, Health, Childhood psychiatric disorders, Amphetamine, Educational psychology, Developmental disorder, Stimulant, Attention deficit hyperactivity disorder controversies, Adult attention deficit hyperactivity disorder

The "Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment" report has been added to ResearchAndMarkets.com's offering.
  • The Global Attention Deficit Hyperactivity Disorder (ADHD) Treatment market is expected to reach $34.1 billion by 2026 growing at a CAGR of 7.7% during the forecast period.
  • Increasing awareness regarding neuro-developmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth.
  • However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.

Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

Retrieved on: 
Monday, November 11, 2019
Psychoactive drugs, Drugs, Branches of biology, Amphetamine, TAAR1 agonists, Methylphenidate, Childhood psychiatric disorders, Stimulant, Attention deficit hyperactivity disorder, Adult attention deficit hyperactivity disorder, Norepinephrine, Attention deficit hyperactivity disorder management

SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.

Key Points: 
  • SPN-812 is a well differentiated product candidate that, if approved by the FDA, can become a unique multi-symptom treatment option for many patients with ADHD.
  • In addition, we announced last week that we initiated a Phase III program to study SPN-812 in the adult ADHD patient population.
  • SPN-812 is a serotonin norepinephrine modulating agent (SNMA) that Supernus is developing as a novel non-stimulant for the treatment of ADHD.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

The attention deficit hyperactivity disorder (ADHD) drugs market will register a CAGR of almost 6% by 2023

Retrieved on: 
Wednesday, June 12, 2019
Psychiatry, Attention deficit hyperactivity disorder, Health, Articles, Childhood psychiatric disorders, Psychiatric diagnosis, Educational psychology, Methylphenidate, Attention deficit, Attention deficit hyperactivity disorder controversies, Adult attention deficit hyperactivity disorder

The rising incidence rate of ADHD among children is one of the critical factors that will trigger the growth of the attention deficit hyperactivity disorder drugs market.

Key Points: 
  • The rising incidence rate of ADHD among children is one of the critical factors that will trigger the growth of the attention deficit hyperactivity disorder drugs market.
  • Our analysts have predicted that the attention deficit hyperactivity disorder (ADHD) drugs market will register a CAGR of almost 6% by 2023.
  • For the detailed list of factors that will drive and challenge the growth of the attention deficit hyperactivity disorder (ADHD) drugs market during 2019-2023, view our report.
  • Factors such as the rising incidence rate of ADHD among children and the increasing government support will provide considerable growth opportunities to attention deficit hyperactivity disorder drugs manufactures.